Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

38.00

Mkt cap

2.4B

Volume

296K

High

39.20

P/E Ratio

-20.40

52-wk high

58.26

Low

37.84

Div yield

N/A

52-wk low

36.52

MoonLake (NASDAQ:MLTX) reported a Q2 2024 adjusted EPS of $(0.39), missing the analyst consensus estimate of $(0.28) by 39.29%.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:41 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 10:41 am

Oppenheimer has initiated coverage on MoonLake (NASDAQ:MLTX) with an Outperform rating and a price target of $104.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 9:48 am

HC Wainwright & Co. has reiterated its Buy rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $100.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 10:35 am

Needham analyst Serge Belanger has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 5:49 pm

MoonLake Immunotherapeutics announced that both the FDA and EMA have unanimously supported the company's proposed approach for advancing its Phase 3 program of the nanobody Sonelokimab in treating psoriatic arthritis.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:04 pm

HC Wainwright & Co. has reiterated its Buy rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $100.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 2:17 pm

MoonLake Immunotherapeutics has initiated the Phase 3 VELA program for its Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa. The program will use the HiSCR75 clinical response level as the primary endpoint, with topline results expected by mid-2025.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 12:10 pm

Diodes Incorporated shares fell by approximately 10% after reporting quarterly financial results that missed market expectations. Other stocks experienced significant movements, with notable gainers including Novavax, Inc. and iTeos Therapeutics, Inc., and losers like MacroGenics, Inc. and Greenwave Technology Solutions, Inc.

Portfolio Pulse from Avi Kapoor

May 10, 2024 | 4:44 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 7:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.